Status:
COMPLETED
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Tumors
Neoplasm Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors
- No tumor spread to the brain
- Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.)
- Available tumor tissue sample from prior surgery
- 4-6 weeks since prior therapy and recovered from prior therapy
- Men and women, ages 18 and above
- Women must not be pregnant or breastfeeding
- Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer
- Measurable disease on scans (at least one)
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT00207103
Start Date
September 1 2004
End Date
September 1 2008
Last Update
November 4 2008
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Premiere Oncology
Santa Monica, California, United States, 90404
2
Indiana University Med Center
Indianapolis, Indiana, United States, 46202
3
University Of Wisconsin Comprehensive Center
Madison, Wisconsin, United States, 53792
4
Local Institution
Edmonton, Alberta, Canada, T6G 1Z2